Skip to main content
SpringerLink
Log in

Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol. 2010;28:4521–30.

    Article  PubMed  Google Scholar 

  2. Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother. 2009;10:125–33.

    Article  PubMed  CAS  Google Scholar 

  3. Lioznov M, El-Cheikh J Jr, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant. 2010;45:349–53.

    Article  PubMed  CAS  Google Scholar 

  4. Coman T, Bachy E, Michallet M, Socie’ G, Uzunov M, Bourhis JH, et al. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the SFGM-TC. Haematologica. 2012 Nov 9 [Epub ahead of print].

  5. Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118:2413–9.

    Article  PubMed  CAS  Google Scholar 

  6. Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2012 Aug 6 [Epub ahead of print].

Download references

Conflict of interest

SI has received research funding from Celgene Corporation.

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya, 467-8601, Japan

    Tomotaka Suzuki, Shigeru Kusumoto, Tatsuya Yoshida, Fumiko Mori, Asahi Ito, Masaki Ri, Takashi Ishida, Hirokazu Komatsu, Akio Niimi & Shinsuke Iida

Authors
  1. Tomotaka Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeru Kusumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatsuya Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fumiko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Asahi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masaki Ri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takashi Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirokazu Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akio Niimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shinsuke Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeru Kusumoto.

About this article

Cite this article

Suzuki, T., Kusumoto, S., Yoshida, T. et al. Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation. Int J Hematol 97, 540–543 (2013). https://doi.org/10.1007/s12185-013-1301-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-013-1301-4

Keywords

Search

Navigation